IL6 and neoplasm: Modified MUC1 protein-functionalized AuNPs were found to be potent macrophage activators, promoting the release of IL-6, IL-10, IL-12, and TNF-α from peritoneal macrophages and driving predominant M1 polarization, highlighting their potential as a potent tumor vaccine [147].